AppRecs review analysis
AppRecs rating 5.0. Trustworthiness 90 out of 100. Review manipulation risk 24 out of 100. Based on a review sample analyzed.
★★★★★
5.0
AppRecs Rating
Ratings breakdown
5 star
50%
4 star
0%
3 star
0%
2 star
0%
1 star
50%
What to know
✓
Low review manipulation risk
24% review manipulation risk
✓
Credible reviews
90% trustworthiness score from analyzed reviews
About Statin Intolerance
Use the App to
• answer questions to evaluate possible intolerance to a patient’s current statin prescription.
• follow steps to treat and manage a patient who reports muscle symptoms on a statin.
• compare statin characteristics and drug interactions to determine the best cholesterol-lowering therapy for the patient.
The recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined jointly after a clinical evaluation and discussion between the patient and their care provider. The app should not be used by patients to guide their own care.
The information and recommendations in this app are derived from ACC/AHA’s 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, and the prescribing information for each statin. It was developed as part of the American College of Cardiology’s “LDL: Address the Risk” Initiative and further refined and vetted by physicians, physician assistants, nurse practitioners, pharmacists, and other relevant specialties; and through user testing in care settings with patients.
This app was developed as part of the ACC’s LDL: Address the Risk Initiative. Financial support for the app was provided by Amgen. All of the content was independently developed with no sponsor involvement.
Statin Intolerance Screenshots
Tap to Rate:
Reviews for Statin Intolerance
DrJenski
SUPD
For someone with diabetes, statin use is an important part of risk reduction to avoid heart attack and stroke. This app helps clinicians determine who can safely restart taking a statin for their potentially life-saving benefits!
wmdny
Shilling for Amgen
Why the ACC would feel compelled to create a specific sales tool for Amgen or any PCSK9 manufacturer is beyond the ethics of most fellow cardiologists. You know how this is corrupt? Look for a corresponding PCSK9 neurologic side effect reporting app. Can't find it? Yeah. Happy to fund intolerance app for statin, oh whoops our pockets are empty even though this new snake oil is $10k/year.